IDH突变低级别胶质瘤辅助治疗与生存的回顾性多中心评估
结果显示接受放疗、替莫唑胺化疗或联合治疗者无进展生存和总生存均未显著优于术后未接受辅助治疗者,即使在高危患者中亦如此,完全肿瘤切除与更长无进展生存独立相关。
要点
- IDH突变低级别胶质瘤术后辅助治疗未显示PFS和OS获益
- 高危患者中未辅助治疗组PFS和OS仍显著更长
- 完全肿瘤切除与更长PFS独立相关
核心结论
- 在IDH突变低级别胶质瘤中,放疗、替莫唑胺化疗或联合辅助治疗未显著改善PFS和OS。
- 即使在高危患者中,辅助治疗对PFS和OS仍显示显著负面影响。
- 完全肿瘤切除的重要性被强调,≥40岁患者完全切除后是否辅助治疗值得讨论。
研究设计与样本
- 回顾性多中心队列研究,基于288例≥18岁弥漫性WHO II级胶质瘤患者。
- 采用Kaplan-Meier估计和多变量Cox回归模型评估辅助治疗对PFS和OS的影响。
主要发现
- 中位总PFS为3.9年,OS为16.1年。
- 未辅助治疗者PFS和OS显著更长(p=0.003)。
- 高危患者(年龄≥40岁或残留肿瘤)中未辅助治疗组PFS为3.9年 vs 3.1年(p=0.025)。
- 多变量模型中未辅助治疗对PFS(p=0.030)和OS(p=0.009)有显著正面影响;RT+CT影响最显著(PFS p=0.004,HR 2.7;OS p=0.001,HR 20.2)。
关键数值与推荐
- 完全肿瘤切除独立关联更长PFS(p=0.019)。
- 年龄≥40岁、组织病理学诊断和复发未达统计学显著性。
临床怎么用
- 对于IDH突变低级别胶质瘤,应优先实现完全肿瘤切除。
- 辅助治疗(放疗、替莫唑胺或联合)的选择需权衡潜在肿瘤去分化风险,尤其在高危患者中。
- ≥40岁患者完全切除后是否辅助治疗应个体化讨论。
局限性
- 回顾性研究设计。
- 辅助治疗指征可能存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The level of evidence for adjuvant treatment of diffuse WHO grade II glioma (low-grade glioma, LGG) is low. In so-called "high-risk" patients most centers currently apply an early aggressive adjuvant treatment after surgery. The aim of this assessment was to compare progression-free survival (PFS) and overall survival (OS) in patients receiving radiation therapy (RT) alone, chemotherapy (CT) alone, or a combined/consecutive RT+CT, with patients receiving no primary adjuvant treatment after surgery. METHODS: Based on a retrospective multicenter cohort of 288 patients (≥ 18 years old) with diffuse WHO grade II gliomas, a subgroup analysis of patients with a confirmed isocitrate dehydrogenase (IDH) mutation was performed. The influence of primary adjuvant treatment after surgery on PFS and OS was assessed using Kaplan-Meier estimates and multivariate Cox regression models, including age (≥ 40 years), complete tumor resection (CTR), recurrent surgery, and astrocytoma versus oligodendroglioma. RESULTS: One hundred forty-four patients matched the inclusion criteria. Forty patients (27.8%) received adjuvant treatment. The median follow-up duration was 6 years (95% confidence interval 4.8-6.3 years). The median overall PFS was 3.9 years and OS 16.1 years. PFS and OS were significantly longer without adjuvant treatment (p = 0.003). A significant difference in favor of no adjuvant therapy was observed even in high-risk patients (age ≥ 40 years or residual tumor, 3.9 vs 3.1 years, p = 0.025). In the multivariate model (controlled for age, CTR, oligodendroglial diagnosis, and recurrent surgery), patients who received no adjuvant therapy showed a significantly positive influence on PFS (p = 0.030) and OS (p = 0.009) compared to any other adjuvant treatment regimen. This effect was most pronounced if RT+CT was applied (p = 0.004, hazard ratio [HR] 2.7 for PFS, and p = 0.001, HR 20.2 for OS). CTR was independently associated with longer PFS (p = 0.019). Age ≥ 40 years, histopathological diagnosis, and recurrence did not achieve statistical significance. CONCLUSIONS: In this series of IDH-mutated LGGs, adjuvant treatment with RT, CT with temozolomide (TMZ), or the combination of both showed no significant advantage in terms of PFS and OS. Even in high-risk patients, the authors observed a similar significantly negative impact of adjuvant treatment on PFS and OS. These results underscore the importance of a CTR in LGG. Whether patients ≥ 40 years old should receive adjuvant treatment despite a CTR should be a matter of debate. A potential tumor dedifferentiation by administration of early TMZ, RT, or RT+CT in IDH-mutated LGG should be considered. However, these data are limited by the retrospective study design and the potentially heterogeneous indication for adjuvant treatment.
引用
- Paľa A, Coburger J, Scherer M, et al. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment. J Neurosurg. 2019. PMID: 31323633. doi:10.3171/2019.4.JNS183395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。